HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

In diabetes, GLP-1 drugs or metformin linked to lower cancer risk than insulin, 15 years

Louis Nervegna · Jul 05, 2024 · ♥ 12 reactions · 14 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)CancerInsulin resistance & diabetes
AI summary & key facts

A retrospective cohort study with 15 years of follow-up found that diabetic patients on GLP-1 agonists or metformin had considerably lower cancer risk than those on insulin; GLP-1 drugs lowered risk of 10 obesity-associated cancers versus insulin. The poster attributes this to insulin's growth-promoting effects.

In diabetics, use of GLP-1 agonist drugs or metformin was associated with considerably lower risk of cancer than use of insulin.

The followup period was 15 years. This was a retrospective cohort study.

(This result is not surprising, given insulin’s well-known growth promoting properties, which stimulate cancer cell division.)

#metfominHD #glp1HD #cancerHD

medpagetoday.comLink to medpagetoday.comFor people with diabetes, cancer risks were reduced with GLP-1s versus insulinmedpagetoday.com

Research cited

← newer: FDA allows a qualified health claim that yogurt may reduce tolder: U-shaped mortality curves for LDL, BMI, A1C and blood pressu →